CISPLATIN, CYCLOPHOSPHAMIDE VERSUS TAXOL, CARBOPLATIN IN EPITHELIAL OVARIAN CARCINOMA: A CLINICAL TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MODARES GILANI M.; MOUSAVI A.; BEHTASH N.; GHAEM MAGHAMI FATEMEH; MOHAMMADIFARD M.; SOLATANPOUR F.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Tehran University Medical Journal Year:2007 | Volume:64 | Issue:11 Page(s): 38-43

Download Full-Text

Persian Verion

View:

1,361

Download:

Cites:

Information Journal Paper

Title

CISPLATIN, CYCLOPHOSPHAMIDE VERSUS TAXOL, CARBOPLATIN IN EPITHELIAL OVARIAN CARCINOMA: A CLINICAL TRIAL

Author(s)

Keywords

CHEMOTHERAPYQ3

SURVIVALQ3

OVARIAN EPITHELIAL CANCERQ3

OPTIMAL DEBULKING SURGERRQ2

Abstract

Background: Access to a safe and efficient CHEMOTHERAPY regimen for improving the SURVIVAL and live quality is a goal in ovarian carcinoma.Despite surgery is the base treatment of ovarian cancer, but in most patients CHEMOTHERAPY is used due to progression of their disease. This study designed to compare two important CHEMOTHERAPY regimens.Methods: This historical cohort study compared two CHEMOTHERAPY regimen; cisplatin (75mg/m2)+ cyclophosphamide (750mg/m2),versus taxol (175mg/m2)+ carboplatinium (GFR+25)XAUC; between 1998-2005 in valiasr hospital. In this study toxicities of two regimes were compared. The SURVIVAL function in these two groups were analysed with Kaplan-Meire curve.Results: Gastrointestinal and mucosal toxicity were significantly higher in CP group compared TC group (p=0.02). Also there were no significant relation between decrease of serum CA125 and patient remission length in CP group but in other group with decrease of CA125 in lower than three cycle we had an increase in patient remission period. (P=0.02). Disease free interval in cisplatin group was longer versus taxol group (p<0.05), there was no significant difference in overall SURVIVAL in two group.Conclusion: This study revealed that cisplatin plus cyclophosphamide regimen can yet be used as a CHEMOTHERAPY treatment in ovarian cancer. In this study there was no significant benefit in taxol regimen compared CP. In the adjuvant therapy of epithelial ovarian carcinoma.

Cites

No record.

References

No record.

Cite

APA: Copy

MODARES GILANI, M., MOUSAVI, A., BEHTASH, N., GHAEM MAGHAMI, FATEMEH, MOHAMMADIFARD, M., & SOLATANPOUR, F.. (2007). CISPLATIN, CYCLOPHOSPHAMIDE VERSUS TAXOL, CARBOPLATIN IN EPITHELIAL OVARIAN CARCINOMA: A CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 64(11), 38-43. SID. https://sid.ir/paper/38806/en

Vancouver: Copy

MODARES GILANI M., MOUSAVI A., BEHTASH N., GHAEM MAGHAMI FATEMEH, MOHAMMADIFARD M., SOLATANPOUR F.. CISPLATIN, CYCLOPHOSPHAMIDE VERSUS TAXOL, CARBOPLATIN IN EPITHELIAL OVARIAN CARCINOMA: A CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)[Internet]. 2007;64(11):38-43. Available from: https://sid.ir/paper/38806/en

IEEE: Copy

M. MODARES GILANI, A. MOUSAVI, N. BEHTASH, FATEMEH GHAEM MAGHAMI, M. MOHAMMADIFARD, and F. SOLATANPOUR, “CISPLATIN, CYCLOPHOSPHAMIDE VERSUS TAXOL, CARBOPLATIN IN EPITHELIAL OVARIAN CARCINOMA: A CLINICAL TRIAL,” TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), vol. 64, no. 11, pp. 38–43, 2007, [Online]. Available: https://sid.ir/paper/38806/en

Related Journal Papers